Supernus Pharmaceuticals, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Stacy Ku from TD Cowen maintained a Buy rating on the stock and has a $60.00 price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Stacy Ku’s rating is based on a combination of factors including the strong performance of Supernus Pharmaceuticals’ key products and the company’s ability to manage supply challenges. Despite the current supply limitations for Onapgo due to higher than anticipated demand, the management is actively working with suppliers to increase production, indicating that this issue is likely short-term. The company has demonstrated solid financial results with Q3 revenue surpassing expectations and a positive outlook for future growth.
Moreover, the performance of Qelbree has been impressive, with significant year-over-year growth and a promising trajectory as the company focuses on expanding its market share in the adult ADHD segment. The management’s raised guidance for 2025 reflects confidence in the continued success of Qelbree and the initial adoption of Onapgo and Zurzuvae. These factors contribute to a positive outlook for Supernus Pharmaceuticals, justifying the Buy rating.
In another report released on October 31, Bank of America Securities also maintained a Buy rating on the stock with a $65.00 price target.
Based on the recent corporate insider activity of 82 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of SUPN in relation to earlier this year.